Dr David Preiss

  • Honorary Clinical Senior Lecturer (Institute of Cardiovascular and Medical Sciences)

telephone: 01413303076
email: David.Preiss@glasgow.ac.uk

Research interests

David Preiss is a Clinical Senior Lecturer in Metabolic Medicine, based between the BHF Glasgow Cardiovascular Research Centre and the Southern General Hospital. He completed his thesis, examining the links between glycaemia and cardiovascular disease, in 2011/2012 and was awarded the University's Bellahouston medal for this research. His interests lie in the conduct of randomised clinical trials, meta-analyses and epidemiological studies in the area of cardio-metabolic disease including dyslipidaemia and diabetes. Research that has led to international interest includes two major collaborations which established that statin therapy increases the risk of developing new-onset diabetes, plus a further meta-analysis which quantified the effect of intensive glucose control on cardiovascular outcomes. He recently completed an important CSO funded placebo-controlled clinical trial, CAMERA, which was designed to investigate the effect of metformin therapy on carotid intima-media thickness, carotid plaques and other surrogate markers of cardiovascular disease in 180 non-diabetic patients with established coronary heart disease. Other interests include statin intolerance, trials of novel lipid-modifying agents, the development of research capabilities in familial hypercholesterolaemia in Scotland and setting up a platform for high-throughput NMR metabolomics. He has led recent publications in JAMA, the Lancet, Diabetes Care, the European Heart Journal and the American Heart Journal and delivered invited lectures at the American Diabetes Association and European Association for the Study of Diabetes annual meetings. He is co-chair of the Scottish Lipid Forum and was awarded a European Foundation for the Study of Diabetes (EFSD) Rising Star Fellowship in 2013.

Research:

  • CAMERA
  • META-ANALYSIS

Member:

  • Diabetes, Renal, Endocrine and Metabolic Medicine
  • Clinical Trials and Implementation Research Theme

 

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Cardiac biomarkers and the prediction of CVD in Scotland
    Scottish Executive Health Department
    2015 - 2017
     
  • The use of proton nuclear magnetic resonance to investigate dyslipidaemia and small molecule accumulation in chronic kidney disease (ISSF Catalyst)
    Wellcome Trust
    2014 - 2015
     
  • The effect of metformin therapy on NT-proBNP levels in non-diabetic patients with established coronary heart disease
    NHS Greater Glasgow and Clyde
    2013 - 2014
     
  • Pilot project to establish a Scottish wide bio-resource for type 2 diabetes - scoT2bio
    NHS Endowment Funds
    2013 - 2014
     
  • Metabolic phenotyping to study mechanisms by which metformin might reduce cardiovascular risk
    European Foundation for the Study of Diabetes
    2013 - 2014
     
  • Assessing the predictive value of quantitative high-throughput NMR metabolomic analysis for CVD events in a major study of diabetes: ADVANCE
    Chest, Heart & Stroke, Scotland
    2013 - 2015
     
  • A National Audit of Management and Outcomes for Patients with Familial Hypercholesterolaemia in Scotland
    Scottish Government
    2013 - 2013
     
  • The application of a high-throughput NMR metabolomics system to the study of insulin resistance (ISSF Catalyst)
    Wellcome Trust
    2011 - 2014
     

Publications

List by: Type | Date

Jump to: 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Number of items: 64.

2016

Sattar, N., Preiss, D., Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R., Wasserman, S. M., and Raal, F. J. (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology, 4(5), pp. 403-410. (doi:10.1016/S2213-8587(16)00003-6) (PMID:26868195)

Nissen, S. E. et al. (2016) Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA: Journal of the American Medical Association, 315(15), pp. 1580-1590. (doi:10.1001/jama.2016.3608) (PMID:27039291)

Loomis, A. K. et al. (2016) Body mass index and risk of non-alcoholic fatty liver disease: two electronic health record prospective studies. Journal of Clinical Endocrinology and Metabolism, 101(3), pp. 945-952. (doi:10.1210/jc.2015-3444#sthash.lllKQB5m.dpuf) (PMID:26672639)

Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C., Zhao, X.-Q., and Preiss, D. (2016) Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart, 102(3), pp. 198-203. (doi:10.1136/heartjnl-2015-308055) (PMID:26370223)

Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, (doi:10.1002/ejhf.543) (PMID:27114189) (Early Online Publication)

Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, (doi:10.1007/s00125-016-3956-x) (Early Online Publication)

2015

Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi:10.1016/j.jchf.2015.03.014)

Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi:10.1136/bmjopen-2015-007901) (PMID:26275900)

Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi:10.1016/j.jchf.2015.03.013) (PMID:26251086)

Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi:10.1111/dme.12762) (PMID:25818859)

Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi:10.1093/eurheartj/ehv072) (PMID:25802390)

Preiss, D., and Kristensen, S. L. (2015) The new Pooled cohort equations risk calculator. Canadian Journal of Cardiology, 31(5), pp. 613-619. (doi:10.1016/j.cjca.2015.02.001) (PMID:25843167)

Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi:10.1002/ejhf.211) (PMID:25756844)

Preiss, D., and Sattar, N. (2015) Classification of reported statin intolerance. Current Opinion in Lipidology, 26(1), pp. 65-66. (doi:10.1097/MOL.0000000000000149) (PMID:25551804)

Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi:10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)

Preiss, D., and Sattar, N. (2015) Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA: Journal of the American Medical Association, 313(10), pp. 1016-1017. (doi:10.1001/jama.2015.1275) (PMID:25756436)

2014

Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi:10.1111/dom.12320) (PMID:24861892)

Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi:10.1007/s00125-014-3383-9)

Preiss, D. (2014) Do statins reduce microvascular complications in diabetes? Lancet Diabetes and Endocrinology, 2(11), pp. 858-859. (doi:10.1016/S2213-8587(14)70177-9) (PMID:25217179)

Preiss, D., McMurray, J. J., and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi:10.1016/s2213-8587(14)70052-x) (PMID:25439459)

Rankin, N. J., Preiss, D., Welsh, P., Burgess, K. E.V., Nelson, S. M., Lawlor, D. A., and Sattar, N. (2014) The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 237(1), pp. 287-300. (doi:10.1016/j.atherosclerosis.2014.09.024) (PMID:25299963) (PMCID:PMC4232363)

Preiss, D., and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi:10.1007/s11886-014-0506-3) (PMID:24890766)

Preiss, D., Lloyd, S. M., Ford, I., McMurray, J. J.V., Holman, R. R., Welsh, P., Fisher, M., Packard, C. J., and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi:10.1016/S2213-8587(13)70152-9) (PMID:24622715)

Sattar, N., Forrest, E., and Preiss, D. (2014) Non-alcoholic fatty liver disease. British Medical Journal, 2014(349), g4596. (doi:10.1136/bmj.g4596) (PMID:25239614) (PMCID:PMC4168663)

2013

Preiss, D., and Sattar, N. (2013) Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 24(6), pp. 532-533. (doi:10.1097/MOL.0000000000000029)

Perez, A.C., Jhund, P., Preiss, D., Kjekshus, J., and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi:10.1016/j.jacc.2012.12.004)

Preiss, D. (2013) Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Review of Gastroenterology and Hepatology, 7(3), pp. 193-195. (doi:10.1586/EGH.12.79)

Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi:10.1161/STROKEAHA.113.001177)

2012

Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi:10.1136/bmjopen-2012-001925)

Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi:10.1001/jama.2012.8439)

Preiss, D. (2012) Statin therapy and new-onset diabetes: a cause for concern? Maturitas, 72(2), pp. 95-96. (doi:10.1016/j.maturitas.2012.02.014)

Preiss, D., and Sattar, N. (2012) Pharmacotherapy: statins and new-onset diabetes—the important questions. Nature Reviews Cardiology, 9(4), pp. 190-192. (doi:10.1038/nrcardio.2012.15)

Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi:10.1093/eurjhf/hfs067)

Sattar, N., and Preiss, D. (2012) HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 55(6), pp. 1564-1567. (doi:10.1007/s00125-012-2510-8)

2011

Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi:10.1093/ije/dyr172)

Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., and Waugh, N. (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment, 15(38), pp. 1-110. (doi:10.3310/hta15380)

Preiss, D., Sesashai, S.R.K., and Ray, K.K. (2011) Statin therapy dose and risk of new-onset diabetes: reply. JAMA: Journal of the American Medical Association, 306(12), p. 1326. (doi:10.1001/jama.2011.1355)

Preiss, D., and Ray, K.K. (2011) Intensive glucose lowering treatment in type 2 diabetes. British Medical Journal, 343, d4243. (doi:10.1136/bmj.d4243)

Ghouri, N. A., Preiss, D., and Sattar, N. (2011) Reply (Need for a Three-Focused Approach to Nonalcoholic Fatty Liver Disease). Hepatology, 53(5), p. 1774. (doi:10.1002/hep.24138)

Preiss, D., Khunti, K., and Sattar, N. (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 28(1), pp. 19-22. (doi:10.1111/j.1464-5491.2010.03157.x)

Preiss, D., and Sattar, N. (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Current Opinion in Lipidology, 22(6), pp. 460-466. (doi:10.1097/MOL.0b013e32834b4994)

Preiss, D., and Sattar, N. (2011) The case for diabetes screening: ADDITION-Europe. Lancet, 378(9786), pp. 106-108. (doi:10.1016/S0140-6736(11)60819-2)

Preiss, D., Sattar, N., and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi:10.1016/j.ahj.2010.10.019)

Preiss, D. et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA: Journal of the American Medical Association, 305(24), pp. 2556-2564. (doi:10.1001/jama.2011.860)

2010

Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi:10.1016/S0140-6736(09)61965-6)

Preiss, D., Sattar, N., and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi:10.1001/jama.2010.137)

Ghouri, N., Preiss, D., and Sattar, N. (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology, 52(3), pp. 1156-1161. (doi:10.1002/hep.23789)

Preiss, D., and Sattar, N. (2010) HbA1c: a useful cardiovascular risk marker in those without diabetes? Diabetologia, 53(12), pp. 2468-2469. (doi:10.1007/s00125-010-1902-x)

Preiss, D., Welsh, P., Murray, H., Shepherd, J., Packard, C., Macfarlane, P., Cobbe, S., Ford, I., and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi:10.1093/eurheartj/ehq095)

Sattar, N., Preiss, D., Welsh, P., Seshasai, S.R.K., and Ray, K.K. (2010) Statins and risk of incident diabetes Reply. Lancet, 375(9732), pp. 2141-2142.

2009

Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi:10.2337/dc08-1709) (PMID:19196892)

Preiss, D.J., and Sattar, N.A. (2009) Metformin and lactic acidosis Metformin: framed again? British Medical Journal, 339, b5570. (doi:10.1136/bmj.b5570)

Preiss, D., and Sattar, N. (2009) Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology, 71(3), pp. 456-457.

Preiss, D., and Sattar, N. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 70(6), pp. 815-828.

Preiss, D., and Sattar, N. (2009) Metabolic syndrome: collapsing under its own weight? Diabetic Medicine, 26(5), pp. 457-459.

Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.

Ray, K., Seshasai, S., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., and Sattar, N. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 373(9677), pp. 1765-1772. (doi:10.1016/S0140-6736(09)60697-8)

2008

Preiss, D., Sattar, N., Harborne, L., Norman, J.E., and Fleming, R. (2008) The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 62(9), pp. 1337-1343. (doi:10.1111/j.1742-1241.2008.01825.x)

Preiss, D., Todd, L., and Panarelli, M. (2008) Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results. Annals of Clinical Biochemistry, 45(1), pp. 70-75. (doi:10.1258/acb.2007.007100)

Preiss, D., and Sattar, N. (2008) Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science, 115(5-6), pp. 141-150.

2007

Preiss, D.J., Godber, I.M., Lamb, E.J., Dalton, R.N., and Gunn, I.R. (2007) The influence of a cooked-meat meal on estimated glomerular filtration rate. Annals of Clinical Biochemistry, 44(1), pp. 35-42. (doi:10.1258/000456307779595995)

Preiss, D.J., and Sattar, N. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? International Journal of Clinical Practice, 61(4), pp. 697-701. (doi:10.1111/j.1742-1241.2007.01330.x)

2006

Preiss, D., and Sattar, N. (2006) Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart, 93(12), pp. 1493-1496. (doi:10.1136/hrt.2007.130849)

Preiss, D.J., Godber, I.M., and Gunn, I.R. (2006) How to measure renal function in clinical practice: Eating cooked meat alters serum creatinine concentration and eGFR significantly. BMJ, 333(7577), p. 1072. (doi:10.1136/bmj.39030.730949.3A)

This list was generated on Tue Jun 28 10:47:25 2016 BST.
Jump to: Articles
Number of items: 64.

Articles

Sattar, N., Preiss, D., Robinson, J. G., Djedjos, C. S., Elliott, M., Somaratne, R., Wasserman, S. M., and Raal, F. J. (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology, 4(5), pp. 403-410. (doi:10.1016/S2213-8587(16)00003-6) (PMID:26868195)

Nissen, S. E. et al. (2016) Efficacy and tolerability of evolocumab vs. ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA: Journal of the American Medical Association, 315(15), pp. 1580-1590. (doi:10.1001/jama.2016.3608) (PMID:27039291)

Loomis, A. K. et al. (2016) Body mass index and risk of non-alcoholic fatty liver disease: two electronic health record prospective studies. Journal of Clinical Endocrinology and Metabolism, 101(3), pp. 945-952. (doi:10.1210/jc.2015-3444#sthash.lllKQB5m.dpuf) (PMID:26672639)

Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C., Zhao, X.-Q., and Preiss, D. (2016) Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials. Heart, 102(3), pp. 198-203. (doi:10.1136/heartjnl-2015-308055) (PMID:26370223)

Jackson, C. E. et al. (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. European Journal of Heart Failure, (doi:10.1002/ejhf.543) (PMID:27114189) (Early Online Publication)

Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D., and McMurray, J. J.V. (2016) SGLT2 and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia, (doi:10.1007/s00125-016-3956-x) (Early Online Publication)

Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi:10.1016/j.jchf.2015.03.014)

Preiss, D. et al. (2015) Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. BMJ Open, 5(8), e007901. (doi:10.1136/bmjopen-2015-007901) (PMID:26275900)

Rush, C. J., Campbell, R. T., Jhund, P. S., Connolly, E. C., Preiss, D., Gardner, R. S., Petrie, M. C., and McMurray, J. J.V. (2015) Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC: Heart Failure, 3(8), pp. 603-614. (doi:10.1016/j.jchf.2015.03.013) (PMID:26251086)

Yates, T. et al. (2015) Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. Diabetic Medicine, 32(8), pp. 1090-1096. (doi:10.1111/dme.12762) (PMID:25818859)

Preiss, D. et al. (2015) The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal, 36(24), pp. 1536-1546. (doi:10.1093/eurheartj/ehv072) (PMID:25802390)

Preiss, D., and Kristensen, S. L. (2015) The new Pooled cohort equations risk calculator. Canadian Journal of Cardiology, 31(5), pp. 613-619. (doi:10.1016/j.cjca.2015.02.001) (PMID:25843167)

Kristensen, S. L. et al. (2015) Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 17(2), pp. 169-176. (doi:10.1002/ejhf.211) (PMID:25756844)

Preiss, D., and Sattar, N. (2015) Classification of reported statin intolerance. Current Opinion in Lipidology, 26(1), pp. 65-66. (doi:10.1097/MOL.0000000000000149) (PMID:25551804)

Swerdlow, D. I. et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet, 385(9965), pp. 351-361. (doi:10.1016/S0140-6736(14)61183-1) (PMID:25262344) (PMCID:PMC4322187)

Preiss, D., and Sattar, N. (2015) Does the LDL receptor play a role in the risk of developing type 2 diabetes? JAMA: Journal of the American Medical Association, 313(10), pp. 1016-1017. (doi:10.1001/jama.2015.1275) (PMID:25756436)

Preiss, D. et al. (2014) Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study. Diabetes, Obesity and Metabolism, 16(12), pp. 1265-1268. (doi:10.1111/dom.12320) (PMID:24861892)

Welsh, P. et al. (2014) Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. Diabetologia, 57(12), pp. 2513-2520. (doi:10.1007/s00125-014-3383-9)

Preiss, D. (2014) Do statins reduce microvascular complications in diabetes? Lancet Diabetes and Endocrinology, 2(11), pp. 858-859. (doi:10.1016/S2213-8587(14)70177-9) (PMID:25217179)

Preiss, D., McMurray, J. J., and Sattar, N. (2014) Treatment of severe hypertriglyceridaemia. Lancet Diabetes and Endocrinology, 2(11), p. 860. (doi:10.1016/s2213-8587(14)70052-x) (PMID:25439459)

Rankin, N. J., Preiss, D., Welsh, P., Burgess, K. E.V., Nelson, S. M., Lawlor, D. A., and Sattar, N. (2014) The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis, 237(1), pp. 287-300. (doi:10.1016/j.atherosclerosis.2014.09.024) (PMID:25299963) (PMCID:PMC4232363)

Preiss, D., and Packard, C. J. (2014) Emerging therapeutic approaches to treat dyslipidemia. Current Cardiology Reports, 16(7), (doi:10.1007/s11886-014-0506-3) (PMID:24890766)

Preiss, D., Lloyd, S. M., Ford, I., McMurray, J. J.V., Holman, R. R., Welsh, P., Fisher, M., Packard, C. J., and Sattar, N. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes and Endocrinology, 2(2), pp. 116-124. (doi:10.1016/S2213-8587(13)70152-9) (PMID:24622715)

Sattar, N., Forrest, E., and Preiss, D. (2014) Non-alcoholic fatty liver disease. British Medical Journal, 2014(349), g4596. (doi:10.1136/bmj.g4596) (PMID:25239614) (PMCID:PMC4168663)

Preiss, D., and Sattar, N. (2013) Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology, 24(6), pp. 532-533. (doi:10.1097/MOL.0000000000000029)

Perez, A.C., Jhund, P., Preiss, D., Kjekshus, J., and McMurray, J.J.V. (2013) Effect of rosuvastatin on fatigue in patients with heart failure. Journal of the American College of Cardiology, 61(10), pp. 1121-1122. (doi:10.1016/j.jacc.2012.12.004)

Preiss, D. (2013) Triglyceride levels, pancreatitis and choice of lipid-modifying therapy. Expert Review of Gastroenterology and Hepatology, 7(3), pp. 193-195. (doi:10.1586/EGH.12.79)

Preiss, D. et al. (2013) Predictors of stroke in patients with impaired glucose tolerance: results from the nateglinide and valsartan in impaired glucose tolerance outcomes research trial. Stroke, 44(9), pp. 2590-2593. (doi:10.1161/STROKEAHA.113.001177)

Preiss, D. et al. (2012) Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial. BMJ Open, 2(6), e001925. (doi:10.1136/bmjopen-2012-001925)

Preiss, D. et al. (2012) Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA: Journal of the American Medical Association, 308(8), pp. 804-811. (doi:10.1001/jama.2012.8439)

Preiss, D. (2012) Statin therapy and new-onset diabetes: a cause for concern? Maturitas, 72(2), pp. 95-96. (doi:10.1016/j.maturitas.2012.02.014)

Preiss, D., and Sattar, N. (2012) Pharmacotherapy: statins and new-onset diabetes—the important questions. Nature Reviews Cardiology, 9(4), pp. 190-192. (doi:10.1038/nrcardio.2012.15)

Preiss, D. et al. (2012) Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure, 14(8), pp. 909-915. (doi:10.1093/eurjhf/hfs067)

Sattar, N., and Preiss, D. (2012) HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia, 55(6), pp. 1564-1567. (doi:10.1007/s00125-012-2510-8)

Ford, I. et al. (2011) The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. International Journal of Epidemiology, 40(6), pp. 1530-1538. (doi:10.1093/ije/dyr172)

Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., and Waugh, N. (2011) Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technology Assessment, 15(38), pp. 1-110. (doi:10.3310/hta15380)

Preiss, D., Sesashai, S.R.K., and Ray, K.K. (2011) Statin therapy dose and risk of new-onset diabetes: reply. JAMA: Journal of the American Medical Association, 306(12), p. 1326. (doi:10.1001/jama.2011.1355)

Preiss, D., and Ray, K.K. (2011) Intensive glucose lowering treatment in type 2 diabetes. British Medical Journal, 343, d4243. (doi:10.1136/bmj.d4243)

Ghouri, N. A., Preiss, D., and Sattar, N. (2011) Reply (Need for a Three-Focused Approach to Nonalcoholic Fatty Liver Disease). Hepatology, 53(5), p. 1774. (doi:10.1002/hep.24138)

Preiss, D., Khunti, K., and Sattar, N. (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabetic Medicine, 28(1), pp. 19-22. (doi:10.1111/j.1464-5491.2010.03157.x)

Preiss, D., and Sattar, N. (2011) Statins and the risk of new-onset diabetes: a review of recent evidence. Current Opinion in Lipidology, 22(6), pp. 460-466. (doi:10.1097/MOL.0b013e32834b4994)

Preiss, D., and Sattar, N. (2011) The case for diabetes screening: ADDITION-Europe. Lancet, 378(9786), pp. 106-108. (doi:10.1016/S0140-6736(11)60819-2)

Preiss, D., Sattar, N., and McMurray, J.J. (2011) A systematic review of event rates in clinical trials in diabetes mellitus: The importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. American Heart Journal, 161(1), p. 210. (doi:10.1016/j.ahj.2010.10.019)

Preiss, D. et al. (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA: Journal of the American Medical Association, 305(24), pp. 2556-2564. (doi:10.1001/jama.2011.860)

Sattar, N. et al. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), pp. 735-742. (doi:10.1016/S0140-6736(09)61965-6)

Preiss, D., Sattar, N., and McMurray, J.J. (2010) Event rates in trials of patients with Type 2 diabetes. JAMA: Journal of the American Medical Association, 303(8), pp. 732-733. (doi:10.1001/jama.2010.137)

Ghouri, N., Preiss, D., and Sattar, N. (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data. Hepatology, 52(3), pp. 1156-1161. (doi:10.1002/hep.23789)

Preiss, D., and Sattar, N. (2010) HbA1c: a useful cardiovascular risk marker in those without diabetes? Diabetologia, 53(12), pp. 2468-2469. (doi:10.1007/s00125-010-1902-x)

Preiss, D., Welsh, P., Murray, H., Shepherd, J., Packard, C., Macfarlane, P., Cobbe, S., Ford, I., and Sattar, N. (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up(dagger). European Heart Journal, 31(10), pp. 1230-1236. (doi:10.1093/eurheartj/ehq095)

Sattar, N., Preiss, D., Welsh, P., Seshasai, S.R.K., and Ray, K.K. (2010) Statins and risk of incident diabetes Reply. Lancet, 375(9732), pp. 2141-2142.

Preiss, D. et al. (2009) Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920. (doi:10.2337/dc08-1709) (PMID:19196892)

Preiss, D.J., and Sattar, N.A. (2009) Metformin and lactic acidosis Metformin: framed again? British Medical Journal, 339, b5570. (doi:10.1136/bmj.b5570)

Preiss, D., and Sattar, N. (2009) Authors' reply to: Statin therapy as the fundamental therapy for cardiovascular prevention: be careful. Clinical Endocrinology, 71(3), pp. 456-457.

Preiss, D., and Sattar, N. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology, 70(6), pp. 815-828.

Preiss, D., and Sattar, N. (2009) Metabolic syndrome: collapsing under its own weight? Diabetic Medicine, 26(5), pp. 457-459.

Preiss, D. et al. (2009) Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 32(5), pp. 915-920.

Ray, K., Seshasai, S., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., and Sattar, N. (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet, 373(9677), pp. 1765-1772. (doi:10.1016/S0140-6736(09)60697-8)

Preiss, D., Sattar, N., Harborne, L., Norman, J.E., and Fleming, R. (2008) The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. International Journal of Clinical Practice, 62(9), pp. 1337-1343. (doi:10.1111/j.1742-1241.2008.01825.x)

Preiss, D., Todd, L., and Panarelli, M. (2008) Diagnosing unsuspected hypopituitarism in adults from suggestive thyroid function test results. Annals of Clinical Biochemistry, 45(1), pp. 70-75. (doi:10.1258/acb.2007.007100)

Preiss, D., and Sattar, N. (2008) Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clinical Science, 115(5-6), pp. 141-150.

Preiss, D.J., Godber, I.M., Lamb, E.J., Dalton, R.N., and Gunn, I.R. (2007) The influence of a cooked-meat meal on estimated glomerular filtration rate. Annals of Clinical Biochemistry, 44(1), pp. 35-42. (doi:10.1258/000456307779595995)

Preiss, D.J., and Sattar, N. (2007) Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis? International Journal of Clinical Practice, 61(4), pp. 697-701. (doi:10.1111/j.1742-1241.2007.01330.x)

Preiss, D., and Sattar, N. (2006) Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence. Heart, 93(12), pp. 1493-1496. (doi:10.1136/hrt.2007.130849)

Preiss, D.J., Godber, I.M., and Gunn, I.R. (2006) How to measure renal function in clinical practice: Eating cooked meat alters serum creatinine concentration and eGFR significantly. BMJ, 333(7577), p. 1072. (doi:10.1136/bmj.39030.730949.3A)

This list was generated on Tue Jun 28 10:47:25 2016 BST.